RxDoctor Payments Data

Mario Montalvo, DO

Pulmonary Disease · Harrisonburg, VANPI 1194103085

Payments from drug & device makers

$3,532in general payments, 2019–2025

Across 25 payments — averaging $141.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Noah Medical Corporation$940
  • Intuitive Surgical$531
  • AstraZeneca$129
  • United Therapeutics Corporation$106
  • Pulmonx Corporation$39

What the payments were for

  • Travel & lodging$2,72577%
  • Food & beverage$80723%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,532 in reported general payments places this provider in the 50th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$105,886
Medicare patients
464
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil11$303,667
OfevNintedanib Esylate15$188,304
Spiriva RespimatTiotropium Bromide87$49,986
Stiolto RespimatTiotropium Br/Olodaterol Hcl77$39,022
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$25,330
Breo ElliptaFluticasone/Vilanterol37$14,453
Fluticasone-SalmeterolFluticasone Propion/Salmeterol88$12,227
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,786
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,896
SymbicortBudesonide/Formoterol Fumarate26$9,422
Pirfenidone14$8,285
BreynaBudesonide/Formoterol Fumarate45$6,922
Varenicline Tartrate32$6,823
Incruse ElliptaUmeclidinium Bromide16$6,522
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$5,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$129$23,52753 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Harrisonburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →